International Multicenter Project Comparing Radiofrequency Ablation Versus Implantable Defibrillator After Well-tolerated Ventricular Tachycardia in Ischemic Heart Disease with Minimally Impaired Ejection Fraction
- Conditions
- Ischemic Heart DiseaseVentricular Tachycardia
- Registration Number
- NCT06294028
- Lead Sponsor
- University Hospital, Toulouse
- Brief Summary
Evidence for the usefulness of the defibrillator in cases of preserved left ventricular ejection fraction and well-tolerated ventricular tachycardia (without cardiocirculatory arrest or syncope) is lacking, as no previous trials have included such patients. Additionally, sudden death in this particular population is low compared to other subgroups of patients with malignant ventricular arrhythmias.
On the other hand, numerous recent retrospective data show that ablation of ventricular tachycardia can reduce mortality, and also clearly reduces the number of recurrences in prospective studies.
Finally, a very low rate of sudden death was observed in a multicenter European retrospective study that we conducted, including patients with well-tolerated ventricular tachycardia in structural heart disease with minimally impaired ejection fraction and benefiting from ablation without implantation of defibrillator.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 268
- ischemic heart disease with history of infarction - LVEF> 35% (measured by MRI)
- sustained monomorphic ventricular tachycardia - without history of syncope or cardiac arrest -
- having signed informed consent
- affiliated to a social security system
- transient regressive cause of ventricular tachycardia
- recent myocardial infarction (<2 months)
- ventricular tachycardia by reentry from branch to branch
- serious conduction disturbances (with indication of stimulation)
- contraindication to the implantation of a defibrillator or to the performance of an ablation (life expectancy <1 year, relevant comorbidities)
- pregnancy
- age <18 years
- Patient under legal protection, guardianship or curatorship
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Monitoring for the occurrence of at least one serious event during the 36 months of follow-up 36 months Monitoring of the occurrence of death from any cause, hospitalization or emergency consultation for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Rangueil Hospital
🇫🇷Toulouse, France
Rangueil Hospital🇫🇷Toulouse, FrancePhilippe MD MAURYContact561341018maury.p@chu-touloue.fr